Has Keith Ridel, MD received payments from drug or device companies?

Yes. Drug and device makers reported $457,045 in general payments to Keith Ridel, MD across 2,029 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Keith Ridel, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Keith Ridel, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Keith Ridel, MD

Neurology with Special Qualifications in Child Neurology · Indianapolis, INNPI 1053528935

Payments from drug & device makers

$457,045in general payments, 2019–2025

Across 2,029 payments — averaging $225.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$216K
Eli Lilly$132K
Eisai Inc.$74K
AbbVie$6K
UCB, Inc.$4K
Jazz Pharmaceuticals Inc.$2K
plus $23K from 54 others

$5,379in research payments, 2019–2025

Across 7 payments — averaging $768.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Arbor Pharmaceuticals, Inc.$3K
Eli Lilly$3K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen(2 entities)	64	$216,407
Eli Lilly	24	$131,743
Eisai Inc.	167	$74,085
AbbVie(2 entities)	302	$5,722
UCB, Inc.	256	$3,894
Jazz Pharmaceuticals Inc.	49	$1,905
SK Life Science, Inc.	64	$1,891
Novartis	110	$1,440
Livanova USA, Inc.	29	$1,315
Biohaven Pharmaceuticals, Inc.	56	$1,226
Pfizer	62	$1,147
Neurocrine Biosciences, Inc.	41	$993
Neurelis, Inc.	41	$923
AstraZeneca(2 entities)	27	$886
Biohaven Pharmaceutical Holding Company Ltd.	59	$836
Lilly USA, LLC	59	$835
Biogen	39	$769
Greenwich Biosciences, Inc.	20	$748
Acadia Pharmaceuticals Inc	25	$714
Supernus Pharmaceuticals, Inc.	97	$650
MDD US Operations, LLC	23	$648
Sanofi	31	$638
Sunovion Pharmaceuticals Inc.	50	$586
EMD Serono, Inc.	29	$404
Catalyst Pharmaceuticals, Inc.	22	$403
Genentech USA, Inc.	24	$397
Teva Pharmaceuticals USA, Inc.	23	$333
Argenx US, Inc.	16	$327
Amneal Pharmaceuticals LLC	14	$283
CSL Behring	14	$281
Banner Life Sciences, LLC	12	$265
Lundbeck LLC	12	$263
TG Therapeutics, Inc.	12	$260
Acorda Therapeutics, Inc	20	$240
Axsome Therapeutics, Inc.	7	$234
Medtronic	4	$214
Takeda Pharmaceuticals U.S.A., Inc.	9	$207
Zogenix Inc.	4	$198
Alnylam Pharmaceuticals Inc.	8	$168
Sumitomo Pharma America, Inc.	9	$166
Vanda Pharmaceuticals Inc.	6	$163
Avanir Pharmaceuticals, Inc.	9	$156
Akcea Therapeutics, Inc.	1	$150
Biocodex, Inc.	3	$150
Mallinckrodt Hospital Products Inc.	3	$138
Grifols USA, LLC	6	$130
Tris Pharma Inc	1	$122
Tanabe Pharma America, Inc.	5	$106
Collegium Pharmaceutical, Inc.	1	$106
Aquestive Therapeutics, Inc.	6	$95
Neuropace, Inc.	1	$93
Johnson & Johnson	4	$82
Otsuka America Pharmaceutical, Inc.	4	$73
GRT US Holding, Inc.	3	$70
Azurity Pharmaceuticals, Inc.	4	$66
PTC Therapeutics, Inc.	2	$61
Aprecia Pharmaceuticals, LLC	3	$54
Ipsen Biopharmaceuticals, Inc	3	$50
Upsher-smith Laboratories LLC	3	$48
Mallinckrodt Enterprises LLC	2	$46

How this compares

$457,045 in reported general payments places this provider in the 95th percentile of 25 neurology with special qualifications in child neurology providers in Indiana.

See all neurology with special qualifications in child neurology providers in Indiana →

Medicare billing

Part B allowed, 2024

$140,025

Medicare patients

482

Services billed

1,620

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology with special qualifications in child neurology in Indianapolis

Christopher JackmanIndianapolis$66K
Kofi QuistIndianapolis$18K
Bittu Majmudar-ShethIndianapolis$1K
Lauren JamesIndianapolis$832
James PappasIndianapolis$780
Lisa McGuireIndianapolis$711
Richard HusseyIndianapolis$348
Makram ObeidIndianapolis$217
Robert BlakeIndianapolis$204
Sarah ElsakrIndianapolis$191

See the full list for Indiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →